Pharming Group (NASDAQ:PHAR) Cut to "Hold" at Zacks Research

Key Points

• Pharming Group's stock was downgraded by Zacks Research from a "strong-buy" to a "hold" rating.
• Despite the downgrade, Pharming Group's stock saw a 6.1% increase, with a current price of $15.39, reflecting a strong performance.
• The company reported a positive quarterly EPS of $0.06, exceeding estimates, and generated $93.20 million in revenue during the same period.

Pharming Group (NASDAQ:PHAR - Get Free Report) was downgraded by equities researchers at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Pharming Group Stock Up 6.1%

PHAR opened at $15.39 on Tuesday. The company has a 50 day moving average of $13.21 and a 200 day moving average of $10.90. The company has a market cap of $1.05 billion, a PE ratio of -118.38 and a beta of 0.04. Pharming Group has a 12 month low of $7.31 and a 12 month high of $17.08. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Pharming Group will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.